‘Fire and forget?’ — pharmacological considerations in coronary care

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1994 • 8,631 citations

The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

1996 • 7,450 citations

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

1995 • 7,378 citations

Goodman and Gilman's the Pharmacological Basis of Therapeutics

1986 • 6,964 citations

Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels

1998 • 5,293 citations

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

1998 • 5,229 citations

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

1994 • 2,716 citations

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1994 • 2,615 citations

Goodman and Gilman's The Pharmacological Basis of Therapeutics

1996 • 2,325 citations

Prevention of coronary heart disease in clinical practice

1994 • 1,133 citations

Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention

1998 • 1,120 citations

Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions

1997 • 755 citations

Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.

1997 • 620 citations

Evolution of the P450 gene superfamily:

1990 • 508 citations

EUROASPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results

1997 • 501 citations

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole*

1998 • 402 citations

Interaction between grapefruit juice and midazolam in humans*

1995 • 360 citations

Disposition of intravenous and oral cyclosporine after administration with grapefruit juice*

1995 • 349 citations

Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins

1997 • 303 citations

Grapefruit juice—simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors*

1998 • 301 citations

Effect of itraconazole on the pharmacokinetics of atorvastatin*

1998 • 295 citations

Atorvastatin

1997 • 281 citations

Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid*

1998 • 272 citations

PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA

2004 • 247 citations

Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.

1990 • 240 citations

Rhabdomyolysis and Renal Injury With Lovastatin Use

1988 • 230 citations

Grapefruit juice–felodipine interaction: Mechanism, predictability, and effect of naringin

1993 • 230 citations

Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man

1998 • 213 citations

Clinical Pharmacokinetics of Pravastatin

2000 • 211 citations

Biotransformation of lovastatin

1991 • 195 citations

Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram*

1996 • 183 citations

Disposition of pravastatin sodium, a tissue‐selective HMG‐CoA reductase inhibitor, in healthy subjects.

1990 • 174 citations

The interaction of diltiazem with lovastatin and pravastatin*

1998 • 173 citations

Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin

1998 • 168 citations

In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase.

1990 • 152 citations

Comparative Pharmacokinetics and Pharmacodynamics of Pravastatin and Lovastatin

1990 • 149 citations

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.

1999 • 144 citations

Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: Incidence, risk factors, and outcome

1993 • 135 citations

The physiological disposition of lovastatin.

1989 • 123 citations

Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue

1996 • 107 citations

Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation.

1995 • 105 citations

Clinical Pharmacokinetics of Pravastatin

1994 • 88 citations

Rhabdomyolysis associated with lovastatin and erythromycin use.

1991 • 83 citations

Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia

1992 • 76 citations

Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved.

1997 • 75 citations

Can grapefruit juice influence ethinylestradiol bioavailability?

1996 • 75 citations

[Rhabdomyolysis in patients treated with simvastatin and cyclosporin: role of the hepatic cytochrome P450 enzyme system activity].

1995 • 38 citations

Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients

1988 • 36 citations

Effects of Simvastatin and Pravastatin on 6β-hydroxycortisol Excretion, a Potential Marker of Cytochrome P-450 3A

1993 • 24 citations

Mortality trends in the coronary care unit.

1990 • 7 citations

Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy

1999 • 3 citations